Becton Dickinson and Company (BDX) Drops 2.48% After Earnings, EPS Tops Expectations and Revenue Tops Expectations

2026-02-09 · Stocks · QuoteReporter

Post Earning Analysis

Becton Dickinson and Company (BDX) Drops 2.48% After Earnings, EPS Tops Expectations and Revenue Tops Expectations

Becton, Dickinson & Co., commonly known as BD, is a leading global medical technology firm founded in 1897. Based in Franklin Lakes, New Jersey, BD specializes in producing medical supplies, devices, laboratory equipment, and diagnostic products across three business segments: BD Medical, BD Life Sciences, and BD Interventional. Each segment focuses on delivering innovative healthcare solutions ranging from medical technologies to diagnostic systems and surgical products.

Becton, Dickinson and Company (BD) recently reported its first-quarter fiscal 2026 financial results, surpassing both earnings and revenue estimates. Despite this positive performance, BD has revised its profit outlook downward following a significant corporate move. The company completed the combination of its Biosciences and Diagnostic Solutions businesses with Waters Corporation, a strategic decision aimed at enhancing its market position and focusing on its core areas.

This restructuring seems to have influenced BD’s financial projections, as the company now anticipates lower profit margins post-spinoff. This news has likely contributed to some volatility in BD’s stock price as investors adjust to the new business structure and future earnings potential. Additionally, Waters Corporation, now integrated with BD’s former units, forecasted a first-quarter profit below Wall Street estimates, which could further impact BD’s stock as market perceptions adjust to the combined entity’s financial outlook. This series of events suggests a period of adjustment for BD, with potential implications for its stock performance as the market evaluates the impacts of these strategic changes.

The current price of the asset is $203.94, reflecting a decline of 2.48% today. This price is significantly below the year-to-date high of $246.65 (-17.32%) and the 52-week high of $231.4 (-11.87%), suggesting a downward trend from annual peaks. However, it remains well above the year-to-date and 52-week lows ($160.6), showing a gain of approximately 27% from these lowest points, indicating overall recovery within the year.

The price is currently below the recent week’s high of $211.47 by about 3.56%, but only slightly above the week’s low of $202.31, suggesting short-term volatility with a slight downward bias in the very recent period.

The Relative Strength Index (RSI) at 51.35 indicates a neutral market momentum, neither overbought nor oversold. The MACD (Moving Average Convergence Divergence) of 1.89, being positive, suggests a bullish signal in the medium term, although this is contradicted by some of the recent price drops.

Looking at moving averages, the price is below the 20-day moving average by 0.39%, but above the 50-day and 200-day moving averages by 2.19% and 9.77% respectively, indicating a stronger performance in a longer-term perspective compared to recent weeks.

Overall, the analysis suggests mixed signals with medium to long-term recovery trends amidst recent short-term volatility and downward pressure. Investors might watch for stabilization or a positive turn in short-term indicators before making further decisions.

BD (Becton, Dickinson and Company) reported its Q1 2026 financial results on February 9, 2026, revealing a total revenue of $5.3 billion, marking a 1.6% increase from $5.2 billion in Q1 2025. This growth is modest at 0.4% on a foreign currency-neutral basis. The company experienced a significant rise in GAAP diluted earnings per share (EPS) to $1.34, up 28.8% from the previous year’s $1.04. However, adjusted diluted EPS saw a decrease of 15.2%, falling to $2.91 from $3.43.

U.S. revenue rose to $3.2 billion, a 2.6% increase, while international revenue was slightly up by 0.2% to $2.1 billion. Segment-wise, Connected Care and Interventional segments showed notable growth of 5.5% and 5.8%, respectively. Conversely, the Life Sciences segment declined by 8.3%.

Operating income improved significantly by 21.8% to $552 million. Net income also increased by 26.1% to $382 million. Despite these gains, net cash from operating activities decreased to $657 million from $693 million.

The company affirmed its full-year fiscal 2026 guidance, projecting low single-digit revenue growth and an adjusted diluted EPS range of $12.35 to $12.65. Additionally, BD announced a strategic combination with Waters Corporation, expected to close concurrently with the earnings announcement.

Earnings Trend Table

The data shows a generally positive trend in the earnings per share (EPS) over the observed quarters from November 2023 to February 2026. The company consistently surpassed EPS estimates except in one instance (November 2023), where it slightly underperformed by -0.16%. This indicates a robust pattern of earnings management and forecasting accuracy.

A notable observation is the significant positive surprise in February 2025, where the reported EPS of 3.43 exceeded the estimate of 2.98 by 15.19%. This suggests a particularly strong quarter relative to expectations. Other quarters, such as February 2024 and May 2024, also show healthy surprises of 11.66% and 6.76%, respectively, indicating strong performance periods.

The smallest positive surprises occurred in November 2024 and May 2025, with surprises of 1.11% and 2.11% respectively, showing closer alignment between estimated and actual EPS. The overall upward trend in both estimated and reported EPS across the quarters suggests growth in earnings, reflecting potentially favorable business conditions or effective strategic initiatives during this period.

Dividend Payments Table

The provided dividend data exhibits a clear upward trend over the observed periods. Initially, dividends were maintained at $0.95 per share from March to September 2024. This consistency suggests a stable financial strategy during these quarters. However, starting from December 2024, there is a noticeable increase in dividends to $1.04 per share, and this elevated level is sustained through three subsequent quarters in 2025. This increment represents a significant shift in dividend policy, potentially indicative of improved financial health or a strategic decision to return more capital to shareholders.

The most recent data point, December 2025, shows a further increase to $1.05 per share. Although this rise is modest, it continues the trend of increasing shareholder value. This progressive increase in dividends could be a positive signal to investors, suggesting confidence from management in the company’s ongoing profitability and cash flow stability.

The most recent rating changes for the stock in question exhibit a mix of optimism and caution from significant financial analysis firms.

1. Citigroup – Resumed – Buy – $233 (2026-02-03): Citigroup resumed coverage on the stock with a “Buy” rating and a target price of $233. This indicates a positive outlook from Citigroup, suggesting substantial upside potential from the current levels. The resumption of coverage, especially with a bullish stance, often reflects new optimism or a reevaluation of the company’s growth prospects and market conditions.

2. RBC Capital Markets – Initiated – Sector Perform – $211 (2025-09-25): RBC Capital Markets initiated coverage with a “Sector Perform” rating and set a target price of $211. This rating implies that the firm expects the stock to perform in line with the average returns of the sector, indicating a neutral view on the stock’s future performance relative to its peers.

3. Citigroup – Downgrade – Buy to Neutral – $185 (2025-05-22): Earlier in the year, Citigroup downgraded the stock from “Buy” to “Neutral” and adjusted the target price to $185. This change suggests a shift in Citigroup’s outlook based on possibly emerging risks or lower-than-expected performance and growth prospects, indicating a more conservative stance on the stock’s valuation and future appreciation potential.

4. Raymond James – Downgrade – Outperform to Market Perform (2025-05-02): Raymond James downgraded their rating from “Outperform” to “Market Perform,” which signifies a change to a neutral stance, aligning the expected performance of the stock with the broader market. Notably, no specific target price was provided, which might indicate uncertainty about the stock’s price direction or a belief that it is fairly valued at current levels.

These rating changes reflect a diverse range of perspectives and suggest a shift from more optimistic views earlier in the year towards a more mixed or neutral outlook as the year progressed. This could be due to changing market dynamics, company performance, or broader economic factors affecting the stock’s perceived value and potential.

The current price of the stock is $203.94. Analyzing the recent analyst ratings, the average target price appears to be $209.67, derived from Citigroup’s target of $233, RBC Capital Markets’ target of $211, and Citigroup’s earlier target of $185. This indicates a potential upside of approximately 2.8% from the current price, suggesting a modest growth expectation.

The ratings from various analysts show a mixed sentiment. Citigroup recently resumed coverage with a “Buy” rating and a target price of $233, indicating a positive outlook. However, earlier in the year, Citigroup downgraded the stock from “Buy” to “Neutral” with a lower target price of $185, reflecting a change in their outlook based on possibly new data or market conditions. Additionally, RBC Capital Markets initiated coverage with a “Sector Perform” rating and a target price of $211, suggesting a neutral stance. Raymond James’ downgrade from “Outperform” to “Market Perform” earlier in the year further aligns with a cautious approach to the stock’s future performance.

This blend of opinions from different analysts could indicate uncertainty or varying expectations based on differing evaluations of the company’s future performance metrics or market conditions.

Disclaimer: The information provided here is for educational and informational purposes only and should not be interpreted as financial advice, investment recommendations, or trading guidance. Markets involve risk, and past performance is not indicative of future results. You should always conduct your own research and consult with a qualified financial advisor before making any investment decisions. By acting, you accept full responsibility for your choices.